ESR1 and cancer: To date, screening for ESR1 in ER+ BC is not considered the standard of care; tumor tissue sampling remains the standard method for addressing tumor biology, despite issues in terms of acquisition and utility; tissue biopsies are invasive and do not have potential complications, and sample preservation may hamper the use of tumor tissue for cancer sequencing (42).